FORWARD PHARMA A/S SPONSORED ADR
(NASDAQ: FWP)

Forward Pharma A/S is a biopharmaceutical company. The Company is focusing to initiate a Phase III clinical trial using FP187, a formulation of dimethyl fumarate (DMF), for the treatment of multiple sclerosis (MS), patients. FP187, the Company�s clinical candidate, is a DMF formulation in a delayed and slow release oral dose, which it plans to advance for the treatment of relapsing remitting MS, or RRMS, and other immune disorders, such as psoriasis.

1.950

- (-%)
Range - - -   (-%)
Open -
Previous Close 1.950
Bid Price -
Bid Volume -
Ask Price -
Ask Volume -
Volume -
Value -
Remark
Delayed prices. Updated at 28 Dec 2022 05:00.
Data powered by
View All Events

About FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS

Forward Pharma A/S is a biopharmaceutical company. The Company is focusing to initiate a Phase III clinical trial using FP187, a formulation of dimethyl fumarate (DMF), for the treatment of multiple sclerosis (MS), patients. FP187, the Company�s clinical candidate, is a DMF formulation in a delayed and slow release oral dose, which it plans to advance for the treatment of relapsing remitting MS, or RRMS, and other immune disorders, such as psoriasis.
Please login to view stock data and analysis